Weight Loss Drug Risks

Ramonabant, a cb one inverse agonist, showed promise in weight loss trials but was later discontinued due to concerns about suicide risk. The drug's impact on the cb one receptor highlights the delicate balance of neurotransmitter signaling for mental health and weight management.